最新观点
Insights From Our Experts
Articles
Making Cutting-Edge Cancer Treatments Accessible: Advancing CAR-T Therapy to the Community Practice
Posted by Anne Marie Robertson , Barry Vucsko , Jordan Schell , Vanith Sankaran, PhD , Jordan Hayes on 3 月 12, 20253/12/25
This article explores the significant advancements in CAR-T therapy and its transition from academic centers to community practices. CAR-T therapy, a revolutionary treatment for certain hematological malignancies, involves modifying a patient’s T-cells to target and destroy…
Association Between Targeted Therapy and Survival in Patients with Myelodysplastic Syndromes
Posted by Pierantonio Russo, MD, FCPP, FAAP, STS , Ramaa Nathan, PhD , Alex Moore, PhD , Daniel Pfeffer, PhD on 12 月 10, 202412/10/24
Precision oncology offers a new approach to cancer care by providing targeted treatments for patients with actionable genetic mutations. However, in the U.S., nearly one-third of eligible patients face barriers such as delayed test results, limited…
Association Between Targeted Therapy and Survival in Patients With Acute Myeloid Leukemia
Posted by Pierantonio Russo, MD, FCPP, FAAP, STS , Ramaa Nathan, PhD , Alex Moore, PhD , Daniel Pfeffer, PhD on 12 月 9, 202412/9/24
Precision oncology innovatively addresses cancer care by targeting treatments to patients with specific biomarker alterations. However, in the U.S., nearly one-third of eligible patients miss out on these life-saving therapies. Operational barriers, physician awareness gaps, slow…
The Importance of Quality-of-Life Metrics in mCRPC
Prostate cancer is one of the most diagnosed malignancies in the world, with many patients progressing to an advanced stage of the disease called metastatic castration-resistant prostate cancer (mCRPC). Due to the poor prognosis and incurable…
Adherence Redefined: Evolving Approaches to Adherence in Oncology Clinical Pathways
Discover how leading cancer institutions are redefining adherence to clinical pathways. Our latest white paper, “Adherence Redefined: Evolving Approaches to Adherence in Oncology Clinical Pathways,” authored by Joey Pecoraro and Christopher Nüesch from EVERSANA MANAGEMENT CONSULTING,…
Comparing First-Line Treatments for mCRPC: Insights From a Comprehensive NMA
Several first-line (1L) pharmacological treatments are available for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC), an incurable condition with poor prognosis and quality of life. Benefits to patient survival in clinical trials have…
Behind the Breakthroughs and Practice-Changing Advances: Insights from ESMO 2024
Every year, the European Society for Medical Oncology (ESMO) brings together experts from pharma, research and advocacy organizations, and healthcare providers (HCPs) to hear about the year’s biggest oncology breakthroughs. With the theme “Shaping the Future…
FDA Guidance and Considerations for Scientific Exchange Communication Strategies
In light of draft guidance issued by the U.S. Food and Drug Administration (FDA) regarding the communication of scientific information of unapproved uses (SIUU) of approved medical medical products, EVERSANA continues to assess the potential risk…
Real-World Effectiveness of Treatments Post-CDK4/6i in Treating HR+/HER2- Locally Advanced or Metastatic Breast Cancer
Since the FDA’s approval of palbociclib plus letrozole in 2015, cyclin-dependent kinase 4/6 inhibitors (CDK4/6i), in combination with endocrine therapy (ET), have become the standard of care for treating hormone receptor-positive, human epidermal growth factor receptor…
Evolving Dynamics in Oncology: Considerations for Overcoming Commercialization Challenges and Driving Greater Impact
The oncology market is experiencing rapid growth, driven by innovations in therapies like biomarker-directed and cell-and-gene therapies. These advancements contribute to improved overall and progression-free survival in various cancer types. However, challenges arise from accelerated approvals…